IRIS
PORTA, Camillo Guglielmo Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.248
AS - Asia 5.812
EU - Europa 5.189
SA - Sud America 2.337
Continente sconosciuto - Info sul continente non disponibili 1.585
AF - Africa 264
OC - Oceania 9
Totale 24.444
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.884
IT - Italia 2.331
SG - Singapore 2.257
BR - Brasile 1.794
HK - Hong Kong 865
CN - Cina 710
VN - Vietnam 689
FR - Francia 494
RU - Federazione Russa 445
SE - Svezia 432
FI - Finlandia 415
DE - Germania 347
GB - Regno Unito 254
ID - Indonesia 233
BD - Bangladesh 217
AR - Argentina 201
IN - India 161
CA - Canada 158
EC - Ecuador 104
IQ - Iraq 93
TR - Turchia 91
MX - Messico 79
CO - Colombia 78
AT - Austria 74
JP - Giappone 74
NL - Olanda 74
PK - Pakistan 69
ZA - Sudafrica 69
ES - Italia 58
SA - Arabia Saudita 57
PH - Filippine 50
VE - Venezuela 49
IE - Irlanda 48
CI - Costa d'Avorio 47
MA - Marocco 41
UZ - Uzbekistan 39
PL - Polonia 37
PY - Paraguay 37
CL - Cile 29
JM - Giamaica 27
JO - Giordania 21
UA - Ucraina 21
KE - Kenya 20
AL - Albania 19
AZ - Azerbaigian 19
BE - Belgio 18
EG - Egitto 18
MY - Malesia 18
NP - Nepal 18
PE - Perù 17
CR - Costa Rica 16
TN - Tunisia 16
LT - Lituania 15
AE - Emirati Arabi Uniti 13
CZ - Repubblica Ceca 13
DO - Repubblica Dominicana 13
UY - Uruguay 13
HN - Honduras 12
BO - Bolivia 11
GT - Guatemala 11
TH - Thailandia 11
ET - Etiopia 10
IL - Israele 10
RO - Romania 10
CH - Svizzera 9
KZ - Kazakistan 9
NI - Nicaragua 9
OM - Oman 9
PT - Portogallo 9
TT - Trinidad e Tobago 9
AU - Australia 8
BH - Bahrain 8
DZ - Algeria 8
KR - Corea 8
RS - Serbia 8
MK - Macedonia 7
PS - Palestinian Territory 7
BG - Bulgaria 6
KG - Kirghizistan 6
LB - Libano 6
PA - Panama 6
PR - Porto Rico 6
QA - Qatar 6
SN - Senegal 6
SY - Repubblica araba siriana 6
AO - Angola 5
TW - Taiwan 5
AM - Armenia 4
BB - Barbados 4
BY - Bielorussia 4
DK - Danimarca 4
HR - Croazia 4
HU - Ungheria 4
LU - Lussemburgo 4
SV - El Salvador 4
BA - Bosnia-Erzegovina 3
BS - Bahamas 3
DM - Dominica 3
GE - Georgia 3
KH - Cambogia 3
Totale 22.787
Salva come PNG Salva come JPEG
Città #
Singapore 1.193
Ashburn 1.075
Hong Kong 845
Milan 838
San Jose 728
Fairfield 648
Council Bluffs 519
Helsinki 400
Cambridge 347
Nyköping 338
Rome 309
Lauterbourg 275
Woodbridge 265
Houston 263
Seattle 259
Bari 251
Dallas 234
Wilmington 230
Chandler 223
Lawrence 221
New York 214
Ho Chi Minh City 213
Roxbury 202
Los Angeles 180
Jakarta 178
Beijing 157
Santa Clara 142
São Paulo 142
Paris 140
Chicago 132
Hanoi 129
Des Moines 122
Falkenstein 122
Columbus 116
Ann Arbor 112
Dong Ket 111
Boardman 107
Buffalo 96
San Diego 88
Inglewood 75
Nuremberg 74
London 72
Figino 68
Salt Lake City 66
Rio de Janeiro 55
Phoenix 52
Frankfurt am Main 50
Abidjan 47
Dublin 47
Turin 47
Brooklyn 44
Belo Horizonte 41
Tokyo 41
Munich 39
Guayaquil 38
Johannesburg 36
Montreal 36
Naples 35
Toronto 35
Tashkent 34
Vienna 34
Baghdad 33
Curitiba 30
Quito 30
Atlanta 28
Manchester 28
Orem 28
Porto Alegre 28
Da Nang 27
Medellín 27
Salvador 27
San Francisco 27
Warsaw 27
Elk Grove Village 26
Haiphong 26
Istanbul 26
Denver 23
Jeddah 23
Lahore 23
Brasília 22
Buenos Aires 22
Caracas 22
Mexico City 22
Chennai 21
Dhaka 21
Campinas 20
Florence 20
Bogotá 19
Guarulhos 19
Amman 18
Amsterdam 18
Asunción 18
Goiânia 18
Moscow 18
Princeton 18
Riyadh 18
Bologna 17
Kingston 17
Miami 17
Baku 16
Totale 14.118
Salva come PNG Salva come JPEG
Nome #
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study 253
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) 181
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 178
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation 175
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 153
The clonal heterogenicity of circulating tumor cells (CTCs) drives their metastatic potential: a new NOD‐SCID melanoma model 151
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice 151
An update on Merkel cell carcinoma 147
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial 146
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification 141
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 141
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer 139
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma 136
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review 132
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial 130
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma 130
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 129
Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma 129
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes 128
Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma 128
Large extracellular vesicles—a new frontier of liquid biopsy in oncology 127
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 127
Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer 125
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial 125
Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review 125
Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art 124
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma 123
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 122
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 120
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies 119
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma 117
Prognostic factors and current treatment strategies for renal cell carcinoma metastatic to the brain: An overview 114
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 113
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 112
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 112
Exploring the Spectrum of Kidney Ciliopathies 112
1101MO Development of CAR T-cells for future treatment of NETs 112
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas 110
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 109
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy 108
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 107
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 104
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale 103
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma 103
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 102
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases 102
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 102
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 101
Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors 101
Beyond ras and braf: Her2, a new actionable oncotarget in advanced colorectal cancer 101
Non-Melanoma Skin Cancers: Biological and Clinical Features 101
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 99
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma 99
Hormone signaling pathways as treatment targets in renal cell cancer (Review) 99
Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model. 99
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? 98
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer 98
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists 97
Primary soft tissue sarcoma of the heart: An emerging chapter in cardio-oncology 96
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study 94
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study 94
Understanding the mechanisms of resistance in EGFR-positive NSCLC: From tissue to liquid biopsy to guide treatment strategy 94
Acute Kidney Injury in Cancer Patients 94
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 94
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer 94
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma 93
Choosing the right cell line for renal cell cancer research 93
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus 93
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival 93
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés 92
Uterine carcinosarcoma: An overview 92
Liquid biopsy in cervical cancer: Hopes and pitfalls 92
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations 91
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 91
[Current approaches to the first-line treatment of clear-cell renal cell carcinoma] 91
Opening an onconephrology clinic: Recommendations and basic requirements 90
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial 90
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study 90
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 89
Adjuvant therapy in renal cell carcinoma 89
A Glimpse in the Future of Malignant Mesothelioma Treatment 89
Abstract 2012: In vitro validation of tumor-derived large extracellular vesicles isolation and characterization as suitable tool for liquid biopsy 88
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer 87
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 87
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 87
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 86
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 86
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 86
Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies 86
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study 84
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma 84
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project 84
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial 84
Playing the devil’s advocate: Should we give a second chance to mTOR inhibition in renal clear cell carcinoma? – ie strategies to revert resistance to mtor inhibitors 84
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells 83
MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management 82
Abstract 2808: Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model 82
Onco-nephrology: A decalogue 82
The role of the cell-cell interactions in cancer progression 82
Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era 81
Totale 10.893
Salva come PNG Salva come JPEG
Categoria #
all - tutte 127.250
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 127.250
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.219 0 0 10 16 66 162 24 40 150 148 226 377
2022/20231.206 236 152 137 22 73 139 138 77 151 10 20 51
2023/2024716 46 240 48 40 54 110 22 39 38 11 13 55
2024/20254.713 207 27 493 256 83 331 473 235 259 370 730 1.249
2025/202612.138 1.294 467 832 1.437 815 622 1.247 611 1.446 1.206 472 1.689
2026/20271.564 648 685 231 0 0 0 0 0 0 0 0 0
Totale 24.444